Literature DB >> 28648841

Fine Needle Aspiration Combined With Matrix-assisted Laser Desorption Ionization Time-of-Flight/Mass Spectrometry to Characterize Lipid Biomarkers for Diagnosing Accuracy of Breast Cancer.

Yi-Tzu Cho1, Hung Su2, Yi-Yan Chiang2, Jentaie Shiea3, Shyng-Shiou F Yuan4, Wen-Chun Hung5, Yao-Tsung Yeh6, Ming-Feng Hou7.   

Abstract

BACKGROUND: Fine needle aspiration (FNA) cytology has been widely used for pathologic assessment of breast lesions. However, the examination suffers a risk of false-negative results owing to insufficient sample volumes, inaccurate sampling positions, nondefinitive cytologic features, or suboptimal cell preservation. One approach to improve its accuracy is using modern mass spectrometry to detect disease biomarkers, of which the tissue samples are collected through FNA.
METHODS: The biological compounds in the FNA tissue samples were extracted and characterized by matrix-assisted laser desorption ionization time-of-flight/mass spectrometry (MALDI-TOF/MS). The results were further analyzed by principal component analysis. Distribution of lipid biomarkers on tissues was explored by imaging mass spectrometry.
RESULTS: Lipid profiles of the tissue samples collected by FNA were rapidly obtained through MALDI-TOF/MS analysis. Phosphatidylcholines and triacylglycerols were detected as the predominant compounds in cancerous and normal regions, respectively. The samples were clearly classified by principal component analysis, based on the differences in their lipid profiles. Different lipid patterns were clearly viewed through the molecular imaging of normal and tumorous regions of breast tissue samples.
CONCLUSION: The FNA-MALDI-TOF/MS approach can provide complementary information for pathological examinations and improve the accuracy of breast cancer diagnoses. Owing to the ease of operation and automation, it is possible to efficiently screen the lipid biomarkers in a large number of tissue samples by means of MALDI-TOF/MS.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FNA; Imaging mass spectrometry; Lipids; MALDI-TOF; PCA

Mesh:

Substances:

Year:  2017        PMID: 28648841     DOI: 10.1016/j.clbc.2017.04.014

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  6 in total

Review 1.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

Review 2.  Mass spectrometry imaging to detect lipid biomarkers and disease signatures in cancer.

Authors:  Matthias Holzlechner; Eliseo Eugenin; Brendan Prideaux
Journal:  Cancer Rep (Hoboken)       Date:  2019-12

3.  Balancing sufficiency and impact in reporting standards for mass spectrometry imaging experiments.

Authors:  Ove J R Gustafsson; Lyron J Winderbaum; Mark R Condina; Berin A Boughton; Brett R Hamilton; Eivind A B Undheim; Michael Becker; Peter Hoffmann
Journal:  Gigascience       Date:  2018-10-01       Impact factor: 6.524

4.  Ex vivo thyroid fine needle aspirations as an alternative for MALDI-MSI proteomic investigation: intra-patient comparison.

Authors:  Isabella Piga; Giulia Capitoli; Francesca Clerici; Allia Mahajneh; Virginia Brambilla; Andrew Smith; Davide Leni; Vincenzo L'Imperio; Stefania Galimberti; Fabio Pagni; Fulvio Magni
Journal:  Anal Bioanal Chem       Date:  2020-12-05       Impact factor: 4.142

Review 5.  Analytical Platforms for the Determination of Phospholipid Turnover in Breast Cancer Tissue: Role of Phospholipase Activity in Breast Cancer Development.

Authors:  Rosa Perestrelo; Marijana Petkovic; Catarina Luís Silva
Journal:  Metabolites       Date:  2021-01-04

Review 6.  Advances in MALDI Mass Spectrometry Imaging Single Cell and Tissues.

Authors:  Xiaoping Zhu; Tianyi Xu; Chen Peng; Shihua Wu
Journal:  Front Chem       Date:  2022-02-03       Impact factor: 5.221

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.